AstraZeneca Sees Malaria Venture Pact As Template For Branching Out Assets Into New Areas
This article was originally published in PharmAsia News
In what it calls a template for future agreements that might further leverage its library of compounds, AstraZeneca has agreed to give Medicines for Malaria Venture a no-charge look at about 500,000 proprietary compounds to see if they have potential in Plasmodium falciparum malaria
You may also be interested in...
HONG KONG - The emergence across Southeast Asia of strains of malaria that display increasing tolerance to the more commonly used therapies could undo years of progress in battling the disease, and public-private partnerships are trying to respond as quickly as possible
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).